Cargando…
RNA interference against polo-like kinase-1 in advanced non-small cell lung cancers
Worldwide, approximately one and a half million new cases of lung cancer are diagnosed each year, and about 85% of lung cancer are non-small cell lung cancer (NSCLC). As the molecular pathogenesis underlying NSCLC is understood, new molecular targeting agents can be developed. However, current thera...
Autores principales: | Kawata, Eri, Ashihara, Eishi, Maekawa, Taira |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3143898/ https://www.ncbi.nlm.nih.gov/pubmed/21884621 http://dx.doi.org/10.1186/2043-9113-1-6 |
Ejemplares similares
-
Targeting the canonical Wnt/β-catenin pathway in hematological malignancies
por: Ashihara, Eishi, et al.
Publicado: (2015) -
Polo-like kinase in trypanosomes: an odd member out of the Polo family
por: Kurasawa, Yasuhiro, et al.
Publicado: (2020) -
Targeting Polo-like kinase 1 and TRAIL enhances apoptosis in non-small cell lung cancer
por: Noor, Alfiah, et al.
Publicado: (2018) -
RNA interference-mediated silencing of the polo-like kinase 1 gene enhances chemosensitivity to gemcitabine in pancreatic adenocarcinoma cells
por: Yu, C, et al.
Publicado: (2008) -
Putting a bit into the polo-box domain of polo-like kinase 1
por: Park, Jung-Eun, et al.
Publicado: (2015)